{
    "2020-09-08": [
        [
            {
                "time": "",
                "orginal_text": "【招银研究|行业跟踪】生物医药行业之医药零售篇——后疫情时代经营加速分化，新一轮并购与上市潮隐现",
                "features": {
                    "keywords": [
                        "生物医药",
                        "医药零售",
                        "后疫情时代",
                        "经营分化",
                        "并购",
                        "上市"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "生物医药",
                        "医药零售"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "湘股中报业绩表现优秀  后疫情时代湖南优势产业逆势扩张",
                "features": {
                    "keywords": [
                        "湘股",
                        "中报业绩",
                        "后疫情时代",
                        "湖南",
                        "优势产业",
                        "逆势扩张"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "湘股",
                        "湖南优势产业"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "医药生物行业周报：二季度业绩逐步恢复 把握业绩确定性",
                "features": {
                    "keywords": [
                        "医药生物",
                        "行业周报",
                        "二季度",
                        "业绩恢复",
                        "业绩确定性"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药生物"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "orginal_text": "四大连锁药房门店扩至2.28万家 拥抱新零售互联网收入成新动能",
                "features": {
                    "keywords": [
                        "连锁药房",
                        "门店扩张",
                        "新零售",
                        "互联网收入",
                        "新动能"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "连锁药房",
                        "新零售"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}